这篇文章不错，转发给_老虎社区_美港股上老虎

2023-08-10

这篇文章不错，转发给大家看看

Benitec Biopharma prices $30M equity offering

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":207257724088384,"tweetId":"207257724088384","gmtCreate":1691629082200,"gmtModify":1691629083340,"author":{"id":4095630847582090,"idStr":"4095630847582090","authorId":4095630847582090,"authorIdStr":"4095630847582090","name":"Fanlization","avatar":"https://static.tigerbbs.com/4ff33c5fed6426a68a814ef72a46d188","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>这篇文章不错，转发给大家看看</body></html>","htmlText":"<html><head></head><body>这篇文章不错，转发给大家看看</body></html>","text":"这篇文章不错，转发给大家看看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/207257724088384","repostId":2358350527,"repostType":2,"repost":{"id":"2358350527","kind":"highlight","pubTimestamp":1691576377,"share":"https://www.laohu8.com/m/news/2358350527?lang=&edition=full","pubTime":"2023-08-09 18:19","market":"us","language":"en","title":"Benitec Biopharma prices $30M equity offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2358350527","media":"seekingalpha","summary":"Benitec Biopharma  priced its underwritten public offering of ~15.54M shares and warrants to purchase up to ~15.54M shares. The offering is expected to close on August 11, 2023. Underwriters have a 30 day option to purchase an additional ~2.33M shares. The aggregate gross proceeds are expected to be ~$30M. Net proceeds from this financing to support the clinical development of BB-301, including the natural history lead-in study and the Phase 1b/2a BB-301 treatment study, for the continued advancement of development activities for other existing and new product candidates, for general corporate purposes and for strategic growth opportunities. The stock price is down 1% before Wednesday market open.","content":"<html><body><p>Benitec Biopharma (<span>NASDAQ:BNTC</span>) priced its underwritten public offering of ~15.54M shares and warrants to purchase up to ~15.54M shares.</p> <p>The offering is expected to close on August 11, 2023.</p> <p>Underwriters have a 30 day option to purchase an additional ~2.33M shares.</p> <p>The aggregate gross proceeds are expected to be ~$30M.</p> <p>Net proceeds from this financing to support the clinical development of BB-301, including the natural history lead-in study and the Phase 1b/2a BB-301 treatment study, for the continued advancement of development activities for other existing and new product candidates, for general corporate purposes and for strategic growth opportunities.</p> <p>The stock price is <span>down 1%</span> before Wednesday market open.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Benitec Biopharma prices $30M equity offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBenitec Biopharma prices $30M equity offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-09 18:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3999845-benitec-biopharma-prices-30m-equity-offering><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Benitec Biopharma (NASDAQ:BNTC) priced its underwritten public offering of ~15.54M shares and warrants to purchase up to ~15.54M shares. The offering is expected to close on August 11, 2023. ...</p>\n\n<a href=\"https://seekingalpha.com/news/3999845-benitec-biopharma-prices-30m-equity-offering\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BNTC":"Benitec Biopharma Limited"},"source_url":"https://seekingalpha.com/news/3999845-benitec-biopharma-prices-30m-equity-offering","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2358350527","content_text":"Benitec Biopharma (NASDAQ:BNTC) priced its underwritten public offering of ~15.54M shares and warrants to purchase up to ~15.54M shares. The offering is expected to close on August 11, 2023. Underwriters have a 30 day option to purchase an additional ~2.33M shares. The aggregate gross proceeds are expected to be ~$30M. Net proceeds from this financing to support the clinical development of BB-301, including the natural history lead-in study and the Phase 1b/2a BB-301 treatment study, for the continued advancement of development activities for other existing and new product candidates, for general corporate purposes and for strategic growth opportunities. The stock price is down 1% before Wednesday market open.","news_type":1},"isVote":1,"tweetType":1,"viewCount":557,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/207257724088384"}